| Trial ID: | L0389 |
| Source ID: | TCTR20210403003
|
| Associated Drug: |
Rilpivirine
|
| Title: |
Effect after Switching from Efavirenz to Rilpivirine on Liver Steatosis Among People Living with HIV with Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
We aimed at comparing the impact of switching from efavirenz to rilpivirine in patients receiving efavirenz plus 2 nucleoside analogues versus continuing with the same therapy on hepatic steatosis as measured by controlled attenuation parameter (CAP) amo
|
| Interventions: |
The group that switched from efavirenz to rilpivirine was changed to the following antiretroviral drugs<br><br>In the case of receiving 3 antiviral drugs and separate tablets for each type or two types of antiviral drugs that do not contain efavirenz in t
|
| Outcome Measures: |
change of controlled attention parameter 24 weeks after randomization fibroscanchange of hepatic fibrosis 24 weeks after randomization fibroscan,Effect on metabolic conditions 24 week after randomization body weight, body mass index, waist circumference, Fasting blood sugar and lipid profile
|
| Sponsor/Collaborators: |
Thai AIDs Society
|
| Gender: |
All
|
| Age: |
18 Years80 Years
|
| Phases: |
Phase 4
|
| Enrollment: |
54
|
| Study Type: |
Interventional
|
| Study Designs: |
Randomized
|
| Start Date: |
03/04/2021
|
| Completion Date: |
30/11/2021
|
| Results First Posted: |
--
|
| Last Update Posted: |
7 February 2022
|
| Locations: |
Thailand
|
| URL: |
www.thaiclinicaltrials.org/show/TCTR20210403003
|
